Oppenheimer & Co. Inc. Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Oppenheimer & Co. Inc. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 28.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,487 shares of the biopharmaceutical company’s stock after acquiring an additional 23,078 shares during the period. Oppenheimer & Co. Inc. owned 0.09% of Catalyst Pharmaceuticals worth $2,181,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Larson Financial Group LLC increased its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. KBC Group NV increased its position in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $134,000. Finally, Quantbot Technologies LP bought a new stake in Catalyst Pharmaceuticals in the third quarter worth $151,000. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on CPRX. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Robert W. Baird started coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price objective on the stock. Stephens reaffirmed an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Stock Up 5.7 %

Shares of Catalyst Pharmaceuticals stock opened at $22.89 on Monday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $24.64. The company’s 50 day moving average is $22.24 and its 200 day moving average is $21.44. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 19.40, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.